TFF3 and HER2 expression and their correlation with survival in gastric cancer

详细信息    查看全文

• 作者：Jianchun Gu ; Leizhen Zheng ; Li Zhang ; Siyu Chen ; Meiling Zhu ; Xiaoping Li…
• 关键词：HER2 ; TFF3 ; Gastric cancer ; Prognosis
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：36
• 期：4
• 页码：3001-3007
• 全文大小：880 KB
• 参考文献：1.Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-0.View Article PubMed
  2.Gonzalez CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2012;130:745-3.View Article PubMed
  3.Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes–a systematic review. Int J Cancer. 2012;130:2845-6.View Article PubMed
  4.Gu J, Zheng L, Wang Y, et al. Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. Tumour Biol. 2014;35:5315-1.View Article PubMed
  5.Hoffmann W. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell Mol Life Sci. 2005;62:2932-.View Article PubMed
  6.Hoffmann W, Jagla W, Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol. 2001;16:319-4.PubMed
  7.John R, El-Rouby NM, Tomasetto C, et al. Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol. 2007;22:743-1.PubMed
  8.Dhar DK, Wang TC, Tabara H, et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res. 2005;11:6472-.View Article PubMed
  9.Meng JR, Tang HZ, Zhou KZ, et al. TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clin Exp Med. 2013;13:297-03.View Article PubMed
  10.Ding A, Zhao W, Shi X, et al. Impact of NPM, TFF3 and TACC1 on the prognosis of patients with primary gastric cancer. PLoS One. 2013;8:e82136.View Article PubMed Central PubMed
  11.Xu CC, Yue L, Wei HJ, et al. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma. Pathol Res Pract. 2013;209:479-5.View Article PubMed
  12.Lauwers GY, Carneiro F, Graham DY. Gastric carcinoma. In: Bowman FT, Carneiro F, Hruban RH, editors. Classification of tumours of the digestive system. Lyon: IARC; 2010.
  13.Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. Chichester: Wiley; 2010.
  14.Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-05.View Article PubMed
  15.Muskett FW, May FE, Westley BR, et al. Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry. 2003;42:15139-7.View Article PubMed
  16.Suemori S, Lynch-Devaney K, Podolsky DK. Identification and characterization of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein family. Proc Natl Acad Sci U S A. 1991;88:11017-1.View Article PubMed Central PubMed
  17.Podolsky DK, Lynch-Devaney K, Stow JL, et al. Identification of human intestinal trefoil factor Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem. 1993;268:12230.PubMed
  18.Dignass A, Lynch-Devaney K, Kindon H, et al. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest. 1994;94:376-3.View Article PubMed Central PubMed
  19.Xian CJ, Howarth GS, Mardell CE, et al. Temporal changes in TFF3 expression and jejunal morphology during methotrexate-induced damage and repair. Am J Physiol. 1999;277:G785-5.PubMed
  20.Efstathiou JA, Noda M, Rowan A, et al. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci U S A. 1998;95:3122-.View Article PubMed Central PubMed
  21.Emami S, Le Floch N, Bruyneel E, et al. Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J. 2001;15:351-1.View Article PubMed
  22.Ahmed AR, Griffiths AB, Tilby MT, et al. TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol. 2012;180:904-6.View Article PubMed
  23.Leung WK, Yu J, Chan FK, et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol. 2002;197:582-.View Article PubMed
  24.Huang Z, Zhang X, Lu H, et al. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China. BMC Gastroenterol. 2014;14:74.View Article PubMed Central PubMed
  25.Deng J, Zhang R, Pan
• 作者单位：Jianchun Gu (1) (2)
  Leizhen Zheng (1)
  Li Zhang (1)
  Siyu Chen (1)
  Meiling Zhu (1)
  Xiaoping Li (1)
  Yajie Wang (2)
  
  1. Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China
  2. Department of Oncology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

The molecular biomarkers human epidermal growth factor receptor-2 (HER2) and trefoil factor 3 (TFF3) are reported to play important roles in the pathogenesis of gastric cancer (GC). In this study, we investigated the clinicopathological and prognostic significance of TFF3 and HER2 expression in GC and explored the correlation between these two biomarkers. Ninety-two patients who were diagnosed with GC were enrolled. TFF3 and HER2 expression was determined on tumor tissues. The results showed that TFF3 and HER2 were positively expressed in 42.7 and 10.9?% of the cases, respectively. There were significantly higher rates of TFF3 positivity in patients with deep invasive tumors and advanced stage ones. Patients with negative TFF3 staining survived longer than those with the presence of TFF3, with 5-year overall survival (OS) rates of 57.1?±-.1 and 39.5?±-.5?%, respectively (P--.033). However, HER2 positivity was not significantly associated with OS (P--.262). Multivariate analysis demonstrated TFF3 expression to be an independent indicator for short-term survival, with a hazard ratio of 2.327 (95?% confidence interval (CI), 1.202-.507, P--.012). There was a trend that the expression of TFF3 was more frequent in HER2 negative tumors than in HER2 positive ones (positive rates: 16.3 vs. 4.7?%, P--.098). Patients with HER2-negative/TFF3-negative GC presented higher OS than those with other phenotypes (P--.009). This study suggests that TFF3 is an independent indicator for survival in GC, while HER2 is not associated with the outcome. Patients with HER2-negative/TFF3-negative GC have the best outcome.